Skip to content

Journal of Nuclear Medicine

ISSN 2159-662X

3 papers in the library · 100 citations · publishing 2010-2022

Papers

Sort Most recent Most cited

Neurovascular Uncoupling: Multimodal Imaging Delineates the Acute Effects of 3,4-Methylenedioxymethamphetamine

Journal of Nuclear Medicine September 29, 2022 Tudor M. Ionescu, Mario Amend, Tadashi Watabe et al. 19 citations

Psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA) have attracted increasing interest in recent years because of their therapeutic potential in psychiatric disorders. To understand the acute effects of psychedelic drugs in vivo, blood-oxygenation-level-dependent (BOLD) functional MRI (fMRI) has been widely used. In particular, fMRI studies have suggested that MDMA leads to...

The Use of Microdosing in the Development of Small Organic and Protein Therapeutics

Journal of Nuclear Medicine May 25, 2017 Mats Bergström 31 citations

Microdosing as a regulatory concept was introduced to facilitate exploratory studies in humans. The concept involves the use of very low doses of a radionuclide-labeled compound for imaging studies or for assessing plasma pharmacokinetics using equipment that has a highly sensitive readout. The supporting principle is that use of these low doses for a limited time in well-controlled, small...

Radiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET

Journal of Nuclear Medicine October 18, 2010 Anders Ettrup, Mikael Palner, Nic Gillings et al. 50 citations

UNLABELLED: PET brain imaging of the serotonin 2A (5-hydroxytryptamine 2A, or 5-HT(2A)) receptor has been widely used in clinical studies, and currently, several well-validated radiolabeled antagonist tracers are used for in vivo imaging of the cerebral 5-HT(2A) receptor. Access to 5-HT(2A) receptor agonist PET tracers would, however, enable imaging of the active, high-affinity state of...